Effects of Ranolazine and its Combination with Amiodarone on Rapid Pacing-induced Reentrant Atrial Tachycardia in Rabbits
| Autor: | Ioannis Skoularigis, Apostolia Hatziefthimiou, Vassileios Simopoulos, Paschalis-Adam Molyvdas, Rodopi Stamatiou, Isaac Aidonidis, Konstantina Dipla |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Tachycardia
medicine.medical_specialty business.industry Refractory period Effective refractory period Amiodarone Ranolazine Atrial fibrillation medicine.disease antiarrhythmic drugs dronedarone Physiology (medical) Internal medicine medicine Cardiology Repolarization Expert Commentary atrial fibrillation ranolazine medicine.symptom Cardiology and Cardiovascular Medicine business Atrial tachycardia medicine.drug |
| Zdroj: | The Journal of Innovations in Cardiac Rhythm Management |
| ISSN: | 2156-3993 2156-3977 |
| Popis: | Ranolazine (RAN) has previously been shown to lower the onset of cholinergic atrial fibrillation in intact animals; however, its efficacy in the setting of atrial tachycardia (AT) is unknown. The purpose of this study was to investigate the effects of RAN alone or in combination with amiodarone (AMIO) on rapid pacing-evoked right AT in rabbit hearts. Right atrial monophasic action potentials (MAPs) were recorded in 11 anesthetized rabbits, using combination MAP pacing catheters. Vulnerability to AT was tested by employing consecutive trains of rapid burst pacing prior to and after 2.4 mg/kg of RAN alone delivered intravenously and then in combination with 3 mg/kg of AMIO as a 15-minute infusion. Primary endpoints were postdrug AT reproducibility as well as cycle length (CL) and tachycardia duration. MAP duration at 75% repolarization and the effective refractory period (ERP) were assessed during programmed pacing to calculate the atrial postrepolarization refractoriness (aPRR = ERP - MAPD75%). AT was elicited in eight out of 11 rabbits; only these animals were included for further investigation. RAN did not abolish the inducibility of AT in any experiment; however, it prolonged its CL (baseline vs. RAN: 120 ± 16 ms vs. 138 ± 18 ms; p = 0.053). Supplemental AMIO further increased the AT CL (baseline vs. RAN + AMIO: 120 ± 16 ms vs. 152 ± 23 ms; p = 0.006), without affecting arrhythmia reinducibility. Slowing of the tachycardia after RAN or RAN + AMIO was associated with spontaneous termination of the arrhythmia. RAN prolonged the aPRR significantly, while AMIO in addition to RAN potentiated this effect. Neither RAN alone nor its combination with AMIO abolished the elicitation of AT in this model. However, both agents synergistically prolonged the aPRR, resulting in the slowing of AT and promoting spontaneous termination of the arrhythmia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|